X4 Pharmaceuticals (XFOR) Non-Current Assets (2017 - 2025)

X4 Pharmaceuticals' Non-Current Assets history runs 9 years deep, the most recent figure standing at $28.9 million for Q4 2025.

• Quarterly Non-Current Assets fell 15.72% year-over-year to $28.9 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $126.2 million (down 2.57% YoY) and the FY2025 annual result came in at $28.9 million, down 15.72% from the prior year.
• Non-Current Assets was $28.9 million for Q4 2025 at X4 Pharmaceuticals, down from $30.8 million in the prior quarter.
• Across five years, Non-Current Assets topped out at $41.1 million in Q1 2021 and bottomed at $24.8 million in Q1 2024.
• A 5-year average of $31.0 million and a median of $29.1 million in 2021 frame the typical range for Non-Current Assets.
• Annual changes were most pronounced in 2022 — Non-Current Assets tumbled 30.46% — and 2024, when it soared 38.44%.
• X4 Pharmaceuticals' Non-Current Assets stood at $29.3 million in 2021, then decreased by 8.15% to $26.9 million in 2022, then retreated by 6.42% to $25.2 million in 2023, then jumped by 36.1% to $34.3 million in 2024, then decreased by 15.72% to $28.9 million in 2025.
• Business Quant data shows XFOR's Non-Current Assets at $28.9 million in Q4 2025, $30.8 million in Q3 2025, and $32.2 million in Q2 2025.